

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Kriptazen 0.5 mg/ml oral solution for calves.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Halofuginone (as lactate salt)	0.50 mg
-----------------------------------	---------

Excipients:

Benzoic acid (E 210)	1.00 mg
Tartrazine (E 102)	0.03 mg

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Oral solution.
Clear yellow solution.

4. CLINICAL PARTICULARS

4.1. Target species

Cattle (newborn calves).

4.2. Indications for use, specifying the target species

In new born calves:

- Prevention of diarrhoea due to diagnosed *Cryptosporidium parvum*, in farms with history of cryptosporidiosis.
Administration should start in the first 24 to 48 hours of age.
- Reduction of diarrhoea due to diagnosed *Cryptosporidium parvum*.
Administration should start within 24 hours after the onset of diarrhoea.

In both cases, the reduction of oocysts excretion has been demonstrated.

4.3. Contraindications

Do not use on an empty stomach.
Do not use in cases of diarrhoea established for more than 24 hours and in weak animals.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

4.4. Special warnings for each target species

None.

4.5. Special precautions for use

Special precautions for use in animals

Administer after colostrum feeding, or after milk or milk replacer feeding only, using an appropriate device for oral administration. Do not use on an empty stomach. For treatment of anorexic calves, the product should be administered in half a litre of an electrolyte solution. The animals should receive enough colostrum according to good breeding practice.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

- People with known hypersensitivity to the active substance or any of the excipients should administer the veterinary medicinal product with caution.
- Repetitive contact with the product may lead to skin allergies.
- Avoid skin, eye or mucosal contact with the product.
- Wear protective gloves while handling the product.
- In case of skin and eye contact wash the exposed area thoroughly with clean water. If eye irritation persists, seek medical advice.
- Wash hands after use.

4.6. Adverse reactions (frequency and seriousness)

An increase in the level of diarrhoea has been observed in rare cases, in treated animals.

The frequency of adverse reactions is defined using the following convention:

- Very common (more than 1 in 10 animals treated displaying adverse reactions)
- Common (more than 1 but less than 10 animals in 100 animals treated)
- Uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- Rare (more than 1 but less than 10 animals in 10,000 animals treated)
- Very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7. Use during pregnancy, lactation or lay

Not applicable.

4.8. Interaction with other medicinal products and other forms of interaction

None known.

4.9. Amounts to be administered and administration route

For oral use in calves after feeding.

The dosage is: 100 µg of halofuginone / kg bw, once a day for 7 consecutive days; i.e. 2 ml of Kriptazen / 10 kg bw, once a day for 7 consecutive days.

The consecutive treatment should be administered at the same time each day.

Once the first calf has been treated, all the forthcoming new-born calves must be systematically treated as long as the risk for diarrhoea due to *C. parvum* persists.

Bottle without a pump: To ensure a correct dosage, the use of either a syringe or any appropriate device for oral administration is necessary.


Bottle with a pump: To ensure a correct dosage, the most appropriate metering pump should be selected, depending on the weight of the animals to be treated. In cases where the dosing pump is unsuitable for the weight of animals to be treated, either a syringe or any other appropriate device can be used.

4 ml pump

- 1) Choose the dip tube designed for the height of the bottle (the shorter one for the 490 ml bottle and the longer one for the 980 ml bottle) and insert it into the free hole located in the base of the pump cap.
- 2) Remove the cap and the protective seal from the bottle and screw the pump on.



- 3) Remove the protector cap from the tip of the nozzle of the pump.
- 4) Prime the pump by pressing the trigger gently, until a drop appears at the tip of the nozzle.
- 5) Restrain the calf and insert the nozzle of the metering pump into its mouth
- 6) Pull the trigger of the metering pump completely for release of a dose that equals 4 ml of solution. Pull two or three times, respectively, for administration of the desired volume (8 ml for calves weighing more than 35 kg but less than or equal to 45 kg and 12 ml for calves weighing more than 45 kg but less than or equal to 60 kg). For lighter or heavier animals, a precise calculation should be performed (2 ml/10 kg bw).
- 7) Continue using until the bottle is empty. If product remains in the bottle, leave the pump attached until further use.
- 8) Always replace the cap on the tip of the nozzle after use.
- 9) Always replace the bottle in the box.




4 to 12 ml pump

- 1) Choose the dip tube designed for the height of the bottle (the shorter one for the 490 ml bottle and the longer one for the 980 ml bottle) and insert it into the free hole located in the base of the pump cap.
- 2) Remove the cap and the protective seal from the bottle and screw the pump on.



- 3) Remove the protector cap from the tip of the nozzle of the pump.
- 4) To prime the pump, turn the dosage ring and select 60 kg (12 ml).
- 5) Press the trigger gradually with the cannula pointed up, until a drop appears at the tip of the nozzle.
- 6) Turn the ring, in order to select the weight of the calf to be treated.
- 7) Restrain the calf and insert the nozzle of the metering pump into its mouth.
- 8) Pull the trigger of the metering pump completely for release of the adequate dose.
- 9) Continue using until the bottle is empty. If product remains in the bottle, leave the pump attached until further use.
- 10) Always replace the cap on the tip of the nozzle after use.
- 11) Always replace the bottle in the box.



4.10. Overdose (symptoms, emergency procedures, antidotes), if necessary

As symptoms of toxicity may occur at twice the therapeutic dose, it is necessary to apply the recommended dosage strictly. Symptoms of toxicity include diarrhoea, visible blood in faeces, decline in milk consumption, dehydration, apathy and prostration. Should clinical signs of overdosing occur, the treatment must be stopped immediately and the animal fed unmedicated milk or milk replacer. Rehydration may be necessary.

4.11. Withdrawal period(s)

Meat and offal: 13 days.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Other antiprotozoal agents, halofuginone.
ATCvet code: QP51AX.

5.1. Pharmacodynamic properties

The active substance, halofuginone, is an antiprotozoal agent of the quinazolinone derivatives group (nitrogenous polyheterocycles). Halofuginone lactate is a salt whose antiprotozoal properties and efficacy against *Cryptosporidium parvum* have been demonstrated both in *in vitro* conditions and in artificial and natural infections. The compound has a cryptosporidiostatic effect on *Cryptosporidium parvum*. It is mainly active on the free stages of the parasite (sporozoïte, merozoïte). The concentrations to inhibit 50% and 90% of the parasites, in an *in vitro* test system, are $IC_{50} < 0.1 \mu\text{g/ml}$ and IC_{90} of $4.5 \mu\text{g/ml}$, respectively.

5.2. Pharmacokinetic particulars

The bioavailability of the drug in the calf following single oral administration is about 80%. The time necessary to obtain the maximum concentration T_{max} is 11 hours. The maximum concentration in plasma C_{max} is 4 ng/ml. The apparent volume of distribution is 10 l/kg. The plasmatic concentrations of halofuginone after repeated oral administrations are comparable to the pharmacokinetic pattern after single oral treatment. Unchanged halofuginone is the major component in the tissues. Highest values have been found in the liver and the kidney. The product is mainly excreted in the urine. The terminal elimination half-life is 11.7 hours after IV administration and 30.84 hours after single oral administration.

6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Benzoic acid (E 210)
Lactic acid (E 270)
Tartrazine (E 102)
Water, Purified

6.2. Major Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

6.3. Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf-life after first opening the immediate packaging: 6 months.

6.4. Special precautions for storage

Keep the bottle in the outer carton in order to protect from light.
Store upright in the original packaging.

6.5. Nature and composition of immediate packaging

Cardboard box containing one 500 ml bottle (high-density polyethylene) containing 490 ml of solution or one 1000 ml bottle containing 980 ml of solution, sealed with a high density polyethylene cap, with or without a metering pump, with two different lengths dip tubes (22 and 24 cm) made of ethylene-vinyl acetate.

Boxes with a metering pump:

4 ml pump

Each package also contains a plastic metering pump delivering 4 ml volumes and two dip tubes (one to fit a 500 ml bottle and one to fit a 1000 ml bottle).

4 to 12 ml pump

Each package also contains a plastic metering pump delivering 4 to 12 ml and two dip tubes (one to fit a 500 ml bottle and one to fit a 1000 ml bottle).

Not all pack sizes may be marketed.

6.6. Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

The product should not enter watercourses as this may be dangerous for fish and other aquatic organisms.

7. MARKETING AUTHORISATION HOLDER

VIRBAC
1^{ère} avenue – 2065 m – LID
06516 Carros
France

8. MARKETING AUTHORISATION NUMBERS

EU/2/18/234/001-006

9. DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION

Date of first authorisation: 08/02/2019

10. DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.

ANNEX II

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**
- D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

VIRBAC
1^{ère} avenue – 2065 m – LID
06516 Carros
France

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

C. STATEMENT OF THE MRLs

The active substance in Kriptazen is an allowed substance as described in Table 1 of the annex to Commission Regulation (EU) No 37/2010:

Pharmaco- logically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions	Therapeutic classification
Halofuginone	Halofuginone	Bovine	10 µg/kg 25 µg/kg 30 µg/kg 30 µg/kg	Muscle Fat Liver Kidney	Not for use in animals from which milk is produced for human consumption	Antiparasitic agents/ Agents acting against protozoa

The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Specific pharmacovigilance requirements:

PSUR submission for Kriptazen shall be synchronised and submitted at the same frequency as for the reference product, Halocur.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Outer carton

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Kriptazen 0.5 mg/ml oral solution for calves
halofuginone

Carton with bottle only

Refill



Carton with bottle and dosing device



2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Active substance:

halofuginone (as lactate salt)

0.50 mg

3. PHARMACEUTICAL FORM

Oral solution.

4. PACKAGE SIZE

490 ml

980 ml

5. TARGET SPECIES

Cattle (newborn calves).

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use in calves after feeding.

Package without a metering pump:

To ensure a correct dosage, the use of either a syringe or any appropriate device for oral administration is necessary.

Package with a metering pump:

In cases where the dosing pump is unsuitable for the weight of animals to be treated, either a syringe or any other appropriate device can be used.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal periods: Meat and offal: 13 days.

9. SPECIAL WARNING(S), IF NECESSARY
--

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}

Once opened use within 6 months.

Once broached, use by ...

11. SPECIAL STORAGE CONDITIONS

Keep the bottle in the outer carton in order to protect from light.

Store upright in the original packaging.



12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal : read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

VIRBAC
1^{ère} avenue – 2065 m – LID
06516 Carros
France

16. MARKETING AUTHORISATION NUMBER(S)
--

EU/2/18/234/001 (490 ml bottle)
EU/2/18/234/002 (980 ml bottle)
EU/2/18/234/003 (490 ml bottle + 4 ml dosing pump)
EU/2/18/234/004 (980 ml bottle + 4 ml dosing pump)
EU/2/18/234/005 (490 ml bottle + 4-12 ml dosing pump)
EU/2/18/234/006 (980 ml bottle + 4-12 ml dosing pump)

17. MANUFACTURER'S BATCH NUMBER
--

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**Bottle of 490 ml or 980 ml****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Kriptazen 0.5 mg/ml oral solution for calves
halofuginone

2. STATEMENT OF ACTIVE SUBSTANCES**Active substance:**

Halofuginone (as lactate salt)

0.5 mg/ml

3. PHARMACEUTICAL FORM

Oral solution.

4. PACKAGE SIZE

490 ml

980 ml

5. TARGET SPECIES

Cattle (newborn calves).

6. INDICATION(S)**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

For oral use.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal periods: Meat and offal: 13 days.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}
Once opened use within 6 months.

11. SPECIAL STORAGE CONDITIONS

Keep the bottle in the outer carton in order to protect from light.
Store upright in the original packaging.



12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

VIRBAC
1^{ère} avenue – 2065 m – LID
06516 Carros
France

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/18/234/001 (490 ml bottle)
EU/2/18/234/002 (980 ml bottle)
EU/2/18/234/003 (490 ml bottle + 4 ml dosing pump)
EU/2/18/234/004 (980 ml bottle + 4 ml dosing pump)
EU/2/18/234/005 (490 ml bottle + 4-12 ml dosing pump)
EU/2/18/234/006 (980 ml bottle + 4-12 ml dosing pump)

17. MANUFACTURER’S BATCH NUMBER

Lot {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET:

Kriptazen 0.5 mg/ml oral solution for calves

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release:

VIRBAC
1^{ère} avenue – 2065 m – LID
06516 Carros
France

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Kriptazen 0.5 mg/ml oral solution for calves
halofuginone

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains:

Active substance:

Halofuginone (as lactate salt)	0.50 mg
-----------------------------------	---------

Excipients:

Benzoic acid (E 210)	1.00 mg
Tartrazine (E 102)	0.03 mg

Clear yellow solution.

4. INDICATION(S)

Cattle (new born calves):

- Prevention of diarrhoea due to diagnosed *Cryptosporidium parvum*, in farms with history of cryptosporidiosis.
Administration should start in the first 24 to 48 hours of age.
- Reduction of diarrhoea due to diagnosed *Cryptosporidium parvum*.
Administration should start within 24 hours after the onset of diarrhoea.

In both cases, the reduction of oocysts excretion has been demonstrated.

5. CONTRAINDICATIONS

Do not use on an empty stomach.

Do not use in cases of diarrhoea established for more than 24 hours and in weak animals.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. ADVERSE REACTIONS

An increase in the level of diarrhoea has been observed in rare cases in treated animals.

The frequency of adverse reactions is defined using the following convention:

- Very common (more than 1 in 10 animals treated displaying adverse reactions)
- Common (more than 1 but less than 10 animals in 100 animals treated)
- Uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- Rare (more than 1 but less than 10 animals in 10,000 animals treated)
- Very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Cattle (new born calves).

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For oral use in calves after feeding.

The dosage is: 100 µg of halofuginone / kg bw, once a day for 7 consecutive days;
i.e. 2 ml of Kriptazen / 10 kg bw, once a day for 7 consecutive days.

The consecutive treatment should be administered at the same time each day.
Once the first calf has been treated, all the forthcoming new-born calves must be systematically treated as long as the risk for diarrhoea due to *C. parvum* persists.

9. ADVICE ON CORRECT ADMINISTRATION

[Bottle without a pump:] To ensure a correct dosage, the use of either a syringe or any appropriate device for oral administration is necessary.

[Bottle with a 4 ml pump:] To ensure a correct dosage, the most appropriate metering pump should be selected, depending on the weight of the animals to be treated. In cases where the dosing pump is unsuitable for the weight of animals to be treated, either a syringe or any other appropriate device can be used.


4 ml pump

- 1) Choose the dip tube designed for the height of the bottle (the shorter one for the 490 ml bottle and the longer one for the 980 ml) and insert it into the free hole located in the base of the pump cap.
- 2) Remove the cap and the protective seal from the bottle and screw the pump on.



- 3) Remove the protector cap from the tip of the nozzle of the pump.
- 4) Prime the pump by pressing the trigger gently, until a drop appears at the tip of the nozzle.
- 5) Restrain the calf and insert the nozzle of the metering pump into its mouth

- 6) Pull the trigger of the metering pump completely for release of a dose that equals 4 ml of solution. Pull two or three times, respectively, for administration of the desired volume (8 ml for calves weighing more than 35 kg but less than or equal to 45 kg and 12 ml for calves weighing more than 45 kg but less than or equal to 60 kg, respectively). For lighter or heavier animal weights, a precise calculation should be performed (2 ml/10 kg bw).
- 7) Continue using until the bottle is empty. If product remains in the bottle, leave the pump attached until further use.
- 8) Always replace the cap on the tip of the nozzle after use.
- 9) Always replace the bottle in the box.



[Bottle with a 4 to 12 ml pump:] To ensure a correct dosage, the most appropriate metering pump should be selected, depending on the weight of the animals to be treated. In cases where the dosing pump is unsuitable for the weight of animals to be treated, either a syringe or any other appropriate device can be used.


4 to 12 ml pump

- 1) Choose the dip tube designed for the height of the bottle (the shorter one for the 490 ml bottle and the longer one for the 980 ml) and insert it into the free hole located in the base of the pump cap.
- 2) Remove the cap and the protective seal from the bottle and screw the pump on.



- 3) Remove the protector cap from the tip of the nozzle of the pump.
- 4) To prime the pump, turn the dosage ring and select 60 kg (12 ml).
- 5) Press the trigger gradually with the cannula pointed up, until a drop appears at the tip of the nozzle.
- 6) Turn the ring, in order to select the weight of the calf to be treated.
- 7) Restrain the calf and insert the nozzle of the metering pump into its mouth.
- 8) Pull the trigger of the metering pump completely for release of the adequate dose.
- 9) Continue using until the bottle is empty. If product remains in the bottle, leave the pump attached until further use.

- 10) Always replace the cap on the tip of the nozzle after use.
- 11) Always replace the bottle in the box.



NOTE: The package leaflet on the market shall mention either the 4 ml pump or the 4 to 12 ml pump or the refill bottle without a pump as appropriate.

10. WITHDRAWAL PERIOD(S)

Meat and offal: 13 days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Keep the bottle in the outer carton in order to protect from light.

Store upright in the original packaging.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.

Shelf-life after first opening the immediate packaging: 6 months.

12. SPECIAL WARNING(S)

Special precautions for use in animals:

Administer after colostrum feeding, or after milk or milk replacer feeding only, using an appropriate device for oral administration. Do not use on an empty stomach. For treatment of anorexic calves, the product should be administered in half a litre of an electrolyte solution. The animals should receive enough colostrum according to good breeding practice.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

- People with known hypersensitivity to the active substance or any of the excipients should administer the veterinary medicinal product with caution.
- Repetitive contact with the product may lead to skin allergies.
- Avoid skin, eye or mucosal contact with the product.
- Wear protective gloves while handling the product.
- In case of skin and eye contact wash the exposed area thoroughly with clean water. If eye irritation persists, seek medical advice.
- Wash hands after use.

Overdose (symptoms, emergency procedures, antidotes):

As symptoms of toxicity may occur at twice the therapeutic dose, it is necessary to apply the recommended dosage strictly. Symptoms of toxicity include diarrhoea, visible blood in faeces, decline in milk consumption, dehydration, apathy and prostration. Should clinical signs of overdosing occur, the treatment must be stopped immediately and the animal fed unmedicated milk or milk replacer. Rehydration may be necessary.

Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

The product should not enter watercourses as this may be dangerous for fish and other aquatic organisms.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

15. OTHER INFORMATION

Cardboard box with a 500 ml bottle containing 490 ml or a 1000 ml bottle containing 980 ml, with or without a dosing pump.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

VIRBAC BELGIUM NV

Esperantolaan 4

BE-3001 Leuven

Tel nr +32-(0)16 387 260

Lietuva

VIRBAC

1^{ère} avenue 2065 m LID

FR-06516 Carros

Tel: +33-(0)4 92 08 73 00

Република България

VIRBAC

1^{ère} avenue 2065 m LID

FR-06516 Carros

Тел: +33-(0)4 92 08 73 00

Luxembourg/Luxemburg

VIRBAC BELGIUM NV

Esperantolaan 4

BE-3001 Leuven

België

Tel nr +32-(0)16 387 260

Česká republika

VIRBAC

1^{ère} avenue 2065 m LID

FR-06516 Carros

Tel: +33-(0)4 92 08 73 00

Magyarország

VIRBAC HUNGARY KFT

Szent István krt.11.II/21.,

HU-1055 Budapest

Тел: +36703387177

Danmark

VIRBAC Danmark A/S Profilvej 1
DK-6000 Kolding
Tel: +45 75521244

Deutschland

VIRBAC Tierarzneimittel GmbH
Rögen 20
DE-23843 Bad Oldesloe
Tel: +49-(4531) 805 111

Eesti

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Tel: +33-(0)4 92 08 73 00

Ελλάδα

VIRBAC HELLAS A.E.
13^ο χλμ Ε.Ο. Αθηνών - Λαμίας
EL-14452, Μεταμόρφωση
Τηλ.: +30 2106219520
info@virbac.gr

España

VIRBAC ESPAÑA SA
Angel Guimerá 179-181
ES-08950 Esplugues de Llobregat (Barcelona)
Tel. : + 34-(0)93 470 79 40

France

VIRBAC France
13^e rue LID
FR-06517 Carros
service-conso@virbac.fr

Hrvatska

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Tel: + 33-(0)4 92 08 73 00

Ireland

VIRBAC
1^{ère} avenue 2065m LID
FR-06516 Carros
Tel: + 33-(0)4 92 08 73 00

Ísland

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Tel: + 33-(0)4 92 08 73 00

Malta

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Tel: + 33-(0)4 92 08 73 00

Nederland

VIRBAC Nederland BV
Hermesweg 15
NL-3771 ND-Barneveld
Tel nr +31-(0)342 427 127

Norge

VIRBAC Danmark A/S
Profilvej 1
DK-6000 Kolding
Tel: + 45 75521244

Österreich

VIRBAC Österreich GmbH
Hildebrandgasse 27
AT-1180 Wien
Tel: +43-(0)1 21 834 260

Polska

VIRBAC Sp. z o.o.
ul. Puławska 314
PL-02 819 Warszawa
Tel.: + 48 22 855 40 46

Portugal

VIRBAC de Portugal Laboratórios LDA
R.do Centro Empresarial
Ed13-Piso 1- Esc.3
Quinta da Beloura
PT-2710-693 Sintra
Tel: + 351 219 245 020

România

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Tel: + 33-(0)4 92 08 73 00

Slovenija

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
+ 33-(0)4 92 08 73 00

Slovenská republika

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Tel: + 33-(0)4 92 08 73 00

Italia

VIRBAC SRL
Via Ettore Bugatti,
IT-15 20142 Milano
Tel: + 39 02 40 92 47 1

Κύπρος

VIRBAC HELLAS A.E.
13^ο χλμ Ε.Ο. Αθηνών - Λαμίας
EL-14452, Μεταμόρφωση
Τηλ.: +30 2106219520
info@virbac.gr

Latvija

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
Tel: +33-(0)4 92 08 73 00

Suomi/Finland

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
+ 33-(0)4 92 08 73 00

Sverige

VIRBAC Danmark A/S Filial Sverige
SE-171 21 Solna
Tel: +45 75521244

United Kingdom (Northern Ireland)

VIRBAC
1^{ère} avenue 2065 m LID
FR-06516 Carros
+ 33-(0)4 92 08 73 00